Global Acne Vulgaris Treatment Market Insights, Forecast to 2025
Table of Contents
1 Study Coverage
- 1.1 Acne Vulgaris Treatment Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Acne Vulgaris Treatment Market Size Growth Rate by Product
- 1.4.2 CB-0601
- 1.4.3 CJM-112
- 1.4.4 CLS-007
- 1.4.5 Dapsone
- 1.4.6 DFD-10
- 1.4.7 DLX-2323
- 1.4.8 Others
- 1.5 Market by End User
- 1.5.1 Global Acne Vulgaris Treatment Market Size Growth Rate by End User
- 1.5.2 Clinic
- 1.5.3 Hospital
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Acne Vulgaris Treatment Market Size
- 2.1.1 Global Acne Vulgaris Treatment Revenue 2014-2025
- 2.1.2 Global Acne Vulgaris Treatment Sales 2014-2025
- 2.2 Acne Vulgaris Treatment Growth Rate by Regions
- 2.2.1 Global Acne Vulgaris Treatment Sales by Regions
- 2.2.2 Global Acne Vulgaris Treatment Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Acne Vulgaris Treatment Sales by Manufacturers
- 3.1.1 Acne Vulgaris Treatment Sales by Manufacturers
- 3.1.2 Acne Vulgaris Treatment Sales Market Share by Manufacturers
- 3.1.3 Global Acne Vulgaris Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Acne Vulgaris Treatment Revenue by Manufacturers
- 3.2.1 Acne Vulgaris Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Acne Vulgaris Treatment Revenue Share by Manufacturers (2014-2019)
- 3.3 Acne Vulgaris Treatment Price by Manufacturers
- 3.4 Acne Vulgaris Treatment Manufacturing Base Distribution, Product Types
- 3.4.1 Acne Vulgaris Treatment Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Acne Vulgaris Treatment Product Type
- 3.4.3 Date of International Manufacturers Enter into Acne Vulgaris Treatment Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Acne Vulgaris Treatment Sales by Product
- 4.2 Global Acne Vulgaris Treatment Revenue by Product
- 4.3 Acne Vulgaris Treatment Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Acne Vulgaris Treatment Breakdown Data by End User
6 North America
- 6.1 North America Acne Vulgaris Treatment by Countries
- 6.1.1 North America Acne Vulgaris Treatment Sales by Countries
- 6.1.2 North America Acne Vulgaris Treatment Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Acne Vulgaris Treatment by Product
- 6.3 North America Acne Vulgaris Treatment by End User
7 Europe
- 7.1 Europe Acne Vulgaris Treatment by Countries
- 7.1.1 Europe Acne Vulgaris Treatment Sales by Countries
- 7.1.2 Europe Acne Vulgaris Treatment Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Acne Vulgaris Treatment by Product
- 7.3 Europe Acne Vulgaris Treatment by End User
8 Asia Pacific
- 8.1 Asia Pacific Acne Vulgaris Treatment by Countries
- 8.1.1 Asia Pacific Acne Vulgaris Treatment Sales by Countries
- 8.1.2 Asia Pacific Acne Vulgaris Treatment Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Acne Vulgaris Treatment by Product
- 8.3 Asia Pacific Acne Vulgaris Treatment by End User
9 Central & South America
- 9.1 Central & South America Acne Vulgaris Treatment by Countries
- 9.1.1 Central & South America Acne Vulgaris Treatment Sales by Countries
- 9.1.2 Central & South America Acne Vulgaris Treatment Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Acne Vulgaris Treatment by Product
- 9.3 Central & South America Acne Vulgaris Treatment by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Acne Vulgaris Treatment by Countries
- 10.1.1 Middle East and Africa Acne Vulgaris Treatment Sales by Countries
- 10.1.2 Middle East and Africa Acne Vulgaris Treatment Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Acne Vulgaris Treatment by Product
- 10.3 Middle East and Africa Acne Vulgaris Treatment by End User
11 Company Profiles
- 11.1 Common Pharma Inc
- 11.1.1 Common Pharma Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Common Pharma Inc Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Common Pharma Inc Acne Vulgaris Treatment Products Offered
- 11.1.5 Common Pharma Inc Recent Development
- 11.2 Cutanea Life Sciences Inc
- 11.2.1 Cutanea Life Sciences Inc Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Cutanea Life Sciences Inc Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Cutanea Life Sciences Inc Acne Vulgaris Treatment Products Offered
- 11.2.5 Cutanea Life Sciences Inc Recent Development
- 11.3 Dermira Inc
- 11.3.1 Dermira Inc Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Dermira Inc Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Dermira Inc Acne Vulgaris Treatment Products Offered
- 11.3.5 Dermira Inc Recent Development
- 11.4 ELORAC Inc
- 11.4.1 ELORAC Inc Company Details
- 11.4.2 Company Business Overview
- 11.4.3 ELORAC Inc Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 ELORAC Inc Acne Vulgaris Treatment Products Offered
- 11.4.5 ELORAC Inc Recent Development
- 11.5 Ensol Biosciences Inc
- 11.5.1 Ensol Biosciences Inc Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Ensol Biosciences Inc Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Ensol Biosciences Inc Acne Vulgaris Treatment Products Offered
- 11.5.5 Ensol Biosciences Inc Recent Development
- 11.6 Foamix Pharmaceuticals Ltd
- 11.6.1 Foamix Pharmaceuticals Ltd Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Foamix Pharmaceuticals Ltd Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Foamix Pharmaceuticals Ltd Acne Vulgaris Treatment Products Offered
- 11.6.5 Foamix Pharmaceuticals Ltd Recent Development
- 11.7 Galderma SA
- 11.7.1 Galderma SA Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Galderma SA Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Galderma SA Acne Vulgaris Treatment Products Offered
- 11.7.5 Galderma SA Recent Development
- 11.8 GlaxoSmithKline Plc
- 11.8.1 GlaxoSmithKline Plc Company Details
- 11.8.2 Company Business Overview
- 11.8.3 GlaxoSmithKline Plc Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 GlaxoSmithKline Plc Acne Vulgaris Treatment Products Offered
- 11.8.5 GlaxoSmithKline Plc Recent Development
- 11.9 Helix BioMedix Inc
- 11.9.1 Helix BioMedix Inc Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Helix BioMedix Inc Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Helix BioMedix Inc Acne Vulgaris Treatment Products Offered
- 11.9.5 Helix BioMedix Inc Recent Development
- 11.10 Hovione FarmaCiencia SA
- 11.10.1 Hovione FarmaCiencia SA Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Hovione FarmaCiencia SA Acne Vulgaris Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Hovione FarmaCiencia SA Acne Vulgaris Treatment Products Offered
- 11.10.5 Hovione FarmaCiencia SA Recent Development
- 11.11 Lee's Pharmaceutical Holdings Ltd
- 11.12 LEO Pharma A/S
- 11.13 Novabiotics Ltd
- 11.14 Novan Inc
- 11.15 Novartis AG
- 11.16 Paratek Pharmaceuticals Inc
- 11.17 Pfizer Inc
- 11.18 Phosphagenics Ltd
12 Future Forecast
- 12.1 Acne Vulgaris Treatment Market Forecast by Regions
- 12.1.1 Global Acne Vulgaris Treatment Sales Forecast by Regions 2019-2025
- 12.1.2 Global Acne Vulgaris Treatment Revenue Forecast by Regions 2019-2025
- 12.2 Acne Vulgaris Treatment Market Forecast by Product
- 12.2.1 Global Acne Vulgaris Treatment Sales Forecast by Product 2019-2025
- 12.2.2 Global Acne Vulgaris Treatment Revenue Forecast by Product 2019-2025
- 12.3 Acne Vulgaris Treatment Market Forecast by End User
- 12.4 North America Acne Vulgaris Treatment Forecast
- 12.5 Europe Acne Vulgaris Treatment Forecast
- 12.6 Asia Pacific Acne Vulgaris Treatment Forecast
- 12.7 Central & South America Acne Vulgaris Treatment Forecast
- 12.8 Middle East and Africa Acne Vulgaris Treatment Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Acne Vulgaris Treatment Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
The global Acne Vulgaris Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Acne Vulgaris Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Acne Vulgaris Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acne Vulgaris Treatment in these regions.
This research report categorizes the global Acne Vulgaris Treatment market by top players/brands, region, type and end user. This report also studies the global Acne Vulgaris Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Common Pharma Inc
Cutanea Life Sciences Inc
Dermira Inc
ELORAC Inc
Ensol Biosciences Inc
Foamix Pharmaceuticals Ltd
Galderma SA
GlaxoSmithKline Plc
Helix BioMedix Inc
Hovione FarmaCiencia SA
Lee's Pharmaceutical Holdings Ltd
LEO Pharma A/S
Novabiotics Ltd
Novan Inc
Novartis AG
Paratek Pharmaceuticals Inc
Pfizer Inc
Phosphagenics Ltd
Market size by Product
CB-0601
CJM-112
CLS-007
Dapsone
DFD-10
DLX-2323
Others
Market size by End User
Clinic
Hospital
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Acne Vulgaris Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Acne Vulgaris Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Acne Vulgaris Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Acne Vulgaris Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Acne Vulgaris Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acne Vulgaris Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.